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Clinical PerspectiveWhat Is New?Frontal brain activity assessed by near‐infrared spectroscopy was reduced in patients with heart failure.What Are the Clinical Implications?Impaired frontal brain activity was associated with high anxiety status and low cognitive function.

Introduction {#jah34759-sec-0008}
============

The prevalence of depression and/or anxiety disorders has been reported to be several times higher in patients with heart failure (HF) than in the general population,[1](#jah34759-bib-0001){ref-type="ref"}, [2](#jah34759-bib-0002){ref-type="ref"}, [3](#jah34759-bib-0003){ref-type="ref"}, [4](#jah34759-bib-0004){ref-type="ref"} and a substantial proportion of patients with HF also have coexisting cognitive problems.[5](#jah34759-bib-0005){ref-type="ref"}, [6](#jah34759-bib-0006){ref-type="ref"}, [7](#jah34759-bib-0007){ref-type="ref"}, [8](#jah34759-bib-0008){ref-type="ref"} Comorbid mood disorders are associated with increased morbidity, mortality, and medical costs in pateints with HF[9](#jah34759-bib-0009){ref-type="ref"}, [10](#jah34759-bib-0010){ref-type="ref"}, [11](#jah34759-bib-0011){ref-type="ref"}, [12](#jah34759-bib-0012){ref-type="ref"}, [13](#jah34759-bib-0013){ref-type="ref"}, [14](#jah34759-bib-0014){ref-type="ref"}, [15](#jah34759-bib-0015){ref-type="ref"} but are underdiagnosed and undertreated.[16](#jah34759-bib-0016){ref-type="ref"} Cognitive impairment is one of the most common comorbidities in patients with HF[8](#jah34759-bib-0008){ref-type="ref"} and is associated with poor quality of life and self‐care, as well as increased morbidity and mortality.[7](#jah34759-bib-0007){ref-type="ref"}, [17](#jah34759-bib-0017){ref-type="ref"}

It has been recently reported that reduced cerebral blood flow (CBF) may be associated with altered autonomic, mood, cognitive, and language and speech regulation sites in HF patients.[18](#jah34759-bib-0018){ref-type="ref"}, [19](#jah34759-bib-0019){ref-type="ref"}, [20](#jah34759-bib-0020){ref-type="ref"} The neural damage appears on examination by several magnetic resonance imaging (MRI) procedures and is reflected as regional loss of tissue or injury, as measured by manual assessment,[21](#jah34759-bib-0021){ref-type="ref"} voxel‐based morphometry,[18](#jah34759-bib-0018){ref-type="ref"} quantitative T2‐relaxometry,[19](#jah34759-bib-0019){ref-type="ref"} and diffusion tensor imaging[22](#jah34759-bib-0022){ref-type="ref"} procedures.

Recently, the development of near‐infrared spectroscopy (NIRS) has enabled noninvasive and bedside measurements of regional cerebral blood volume in terms of relative concentrations of oxyhemoglobin and deoxyhemoglobin, with a high time resolution. The concentrations of oxyhemoglobin and deoxyhemoglobin are assumed to reflect the regional cerebral blood volume.[23](#jah34759-bib-0023){ref-type="ref"}, [24](#jah34759-bib-0024){ref-type="ref"}, [25](#jah34759-bib-0025){ref-type="ref"} In addition, oxyhemoglobin increases and deoxyhemoglobin decreases in NIRS have been shown to reflect cortical activation by simultaneous measurements with other methodologies,[24](#jah34759-bib-0024){ref-type="ref"} NIRS presents cerebral perfusion, and is used as functional brain monitoring.[23](#jah34759-bib-0023){ref-type="ref"} A positive correlation has been confirmed between oxyhemoglobin concentration by NIRS and blood‐oxygen‐level--dependent signaling by functional MRI.[26](#jah34759-bib-0026){ref-type="ref"}, [27](#jah34759-bib-0027){ref-type="ref"} Further, NIRS has recently been used to investigate the neurocognitive processes associated with neurological (Alzheimer disease, Parkinson disease, epilepsy, and traumatic brain injury) and psychiatric disorders (depression, bipolar disorder, anxiety disorders, and schizophrenia).[28](#jah34759-bib-0028){ref-type="ref"} The frontal NIRS signal has been proposed as a supportive tool in assisting the diagnosis of major psychiatric disorders with depressive symptoms in addition to evaluation of brain activity.[24](#jah34759-bib-0024){ref-type="ref"}, [29](#jah34759-bib-0029){ref-type="ref"}, [30](#jah34759-bib-0030){ref-type="ref"} Compared with positron emission tomography, single‐photon emission computed tomography, and functional MRI, NIRS has the advantages of requiring minimal equipment and being easy to use.

In the present study, we aimed to (1) evaluate and compare frontal brain activity using NIRS in patients with HF and control subjects, and (2) determine the associations between frontal brain activity and depressive symptoms, anxiety status, and cognitive function.

Methods {#jah34759-sec-0009}
=======

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Subjects and Study Protocol {#jah34759-sec-0010}
---------------------------

This is a cross‐sectional study with 28 age‐matched control subjects and 35 patients with HF who came to Fukushima Medical University Hospital between May 2018 and June 2019. The diagnosis of HF was made by several cardiologists on the basis of the HF guidelines.[31](#jah34759-bib-0031){ref-type="ref"}, [32](#jah34759-bib-0032){ref-type="ref"} Study subjects underwent echocardiography, carotid artery ultrasonography, laboratory testing, psychological testing, and NIRS. The verbal fluency task (VFT) is used to test frontal region function and is commonly used with NIRS analysis.[33](#jah34759-bib-0033){ref-type="ref"}, [34](#jah34759-bib-0034){ref-type="ref"} The control subjects were without past history of HF, physical signs of HF, or structural cardiac abnormalities, which were detected by echocardiography. The study protocol was approved by the ethical committee of Fukushima Medical University (no. 823), and the investigation conforms to the principles outlined in the Declaration of Helsinki. All subjects provided written informed consent to participate in the study. Patients with carotid artery stenosis, cerebral infarction, or dementia, or patients receiving treatment for schizophrenia, depression, or bipolar disorder were excluded. We evaluated several comorbidities that often coexist and are associated with adverse prognosis in patients with HF.[35](#jah34759-bib-0035){ref-type="ref"} Regarding the psychological testing, the Center for Epidemiologic Studies Depression Scale (CES‐D) was used to evaluate depressive symptoms,[36](#jah34759-bib-0036){ref-type="ref"}, [37](#jah34759-bib-0037){ref-type="ref"}, [38](#jah34759-bib-0038){ref-type="ref"} the State‐Trait Anxiety Inventory--State (STAI‐S) and STAI--Trait (STAI‐T) were used to evaluate anxiety status and trait,[39](#jah34759-bib-0039){ref-type="ref"} and the Mini‐Mental State Examination (MMSE) was used to evaluate cognitive function.[40](#jah34759-bib-0040){ref-type="ref"} We compared the findings of CES‐D, STAI‐S, MMSE, VFT, and NIRS findings between the patients with HF and control subjects and determined the associations between frontal brain activity and depressive symptoms, anxiety status, and cognitive ability.

Blood samples were obtained from all subjects at Fukushima Medical University Hospital. B‐type natriuretic peptide levels were measured using a specific immunoradiometric assay (Shionoria BNP kit, Shionogi, Osaka, Japan).

Echocardiography and carotid artery ultrasonography were performed blindly by experienced sonographers using standard techniques.[35](#jah34759-bib-0035){ref-type="ref"}, [41](#jah34759-bib-0041){ref-type="ref"} The left ventricular ejection fraction was calculated using Simpson\'s method in a 4‐chamber view.[35](#jah34759-bib-0035){ref-type="ref"}, [41](#jah34759-bib-0041){ref-type="ref"} All measurements were performed using ultrasound systems (ACUSON Sequoia, Siemens Medical Solutions USA, Inc, Mountain View, CA). In the present study, HF with left ventricular ejection fraction ≥45% was defined as HF with preserved ejection fraction, and HF with left ventricular ejection fraction \<45% was defined as HF with reduced ejection fraction.

Measurement of NIRS {#jah34759-sec-0011}
-------------------

A VFT was widely used as an activating task during NIRS analysis, as previously reported.[33](#jah34759-bib-0033){ref-type="ref"}, [34](#jah34759-bib-0034){ref-type="ref"} In the current study, oxyhemoglobin, deoxyhemoglobin, and total hemoglobin were measured with a 52‐channel NIRS machine (Hitachi ETG4000, Hitachi Medical Corp., Tokyo, Japan) using 2 wavelengths of near‐infrared light (695 and 830 nm). NIRS measurement was performed by attaching 52 channels to the head.[29](#jah34759-bib-0029){ref-type="ref"}, [30](#jah34759-bib-0030){ref-type="ref"} The 52‐channel device was connected symmetrically around the prefrontal cortex. The main measured channels were as follows: right temporal lobe (channels 1--3, 11--14, 22--24, 32--35, and 43--45), left temporal lobe (channels 8--10, 18--21, 29--31, 39--42, and 50--52) and frontal region (channels 25--28, 36--38, and 46--49). Especially, an increase in cerebral oxyhemoglobin concentration in the frontal region in response to the VFT is considered as a marker of frontal brain activity.[30](#jah34759-bib-0030){ref-type="ref"}, [42](#jah34759-bib-0042){ref-type="ref"}, [43](#jah34759-bib-0043){ref-type="ref"} Most of the lower and forward channels were placed along the line connecting T3‐Fpz‐T4, based on the international 10‐20 system. Compliance with the scalp measurement sites of the international 10‐20 system allows prediction of the measurement sites on the brain surface with relatively high accuracy. NIRS signal changes were measured during a 10‐second pretask baseline period, a 60‐second activation period, and a 55‐second posttask baseline period. The sampling rate of oxyhemoglobin concentration data was 0.1 second. The obtained data were analyzed using the "integral mode": The pretask baseline was set as the mean over a 10‐second period just before the task period, and the posttask baseline was fixed as the mean over the last 5 seconds of the posttask period. Linear fitting between the pre‐ and posttask baselines was applied to the data between the 2 baselines. The average oxyhemoglobin concentration during the VFT that was performed for 60 seconds was used for the analysis. A previously reported algorithm[33](#jah34759-bib-0033){ref-type="ref"} was used to automatically reject data with artifacts. Data are expressed as waveforms and topographic maps. The intraclass correlation coefficient of the mean oxyhemoglobin concentration during the task segment was calculated for the 52 channels. The single‐measure intraclass correlation coefficient was 0.5309, and the average measure intraclass correlation coefficient was 0.6936, which are both reliable, as previously reported.[44](#jah34759-bib-0044){ref-type="ref"} NIRS analyses were performed using MATLAB R2011 (Math Works Inc, Natick, MA), and Prism 6.0 software (GraphPad Software, Inc, San Diego, CA).

Activation Task, VFT {#jah34759-sec-0012}
--------------------

An outline of the VFT procedure is as follows.[33](#jah34759-bib-0033){ref-type="ref"}, [34](#jah34759-bib-0034){ref-type="ref"} Changes in hemoglobin oxygenation occur in people performing the VFT. Artifacts must be eliminated by having the subject sit in a chair, relax, and move as little as possible during the test. The subject is first prompted by a voice saying, "Start /a/, /i/, /u/, /e/, /o/" to repeat the utterance "/a/, /i/, /u/, /e/, /o/" for 30 seconds. The baseline activity recorded during this meaningless utterance is used to remove the effect of vocalization on brain activity from the data. The subject is next prompted by a voice to vocalize as many words as possible that start with a certain letter. This is done in three 20‐second sets. The subjects are verbally prompted to vocalize words starting with a certain letter to increase the difficulty of the task. The exercise is scored by recording the number of words uttered every 20 seconds. Finally, the subject is prompted by a voice saying, "Stop /a/, /i/, /u/, /e/, /o/" to stop the task and repeat "/a/, /i/, /u/, /e/, /o/" for 70 seconds.

Statistical Analysis {#jah34759-sec-0013}
--------------------

Categorical variables are expressed as numbers and percentages. The chi‐square test was used for comparisons of categorical variables and followed by Fisher\'s exact test when appropriate. Normality was confirmed using the Shapiro‐Wilk test in each group. Normally distributed variables are presented as mean±SD, and non--normally distributed variables (eg, B‐type natriuretic peptide, NIRS finding) are presented as a median and interquartile range. Normally distributed variables were compared using the Student *t* test, whereas non--normally distributed variables were compared using the Mann--Whitney U test. To compare continuous variables among the HF with reduced ejection fraction, HF with preserved ejection fraction, and control subjects, the Kruskal--Wallis test was used. Correlations between each NIRS finding and physiological questionnaire were assessed using Spearman\'s correlation analysis. We used simple linear regression to identify potential confounding variables, and those with a *P*\<0.05 were included in the final multiple linear regression model. A *P* value of \<0.05 was considered statistically significant for all comparisons. All analyses were performed using a statistical software package (SPSS version 24.0, IBM, Armonk, NY).

Results {#jah34759-sec-0014}
=======

The comparisons of clinical features between the control subjects and patients with HF in the present study are shown in Table [1](#jah34759-tbl-0001){ref-type="table"}. B‐type natriuretic peptide was significantly higher, and hemoglobin, estimated glomerular filtration rate, and left ventricular ejection fraction were significantly lower in the patients with HF than in the control subjects. In addition, we found no significant difference in age, sex, percutaneous oxygen saturation, or medication, except for inotropic agents, between the 2 groups. Regarding psychological testing, VFT and MMSE were significantly lower, and STAI‐S was significantly higher in the patients with HF than in the control subjects. In contrast, CES‐D and STAI‐T did not significantly differ between the groups.

###### 

Comparisons of Clinical Features Between the Control Subjects and Patients With Heart Failure

                                                                             Control Subjects (n=28)   Patients With Heart Failure (n=35)   *P* Value
  -------------------------------------------------------------------------- ------------------------- ------------------------------------ -----------
  Demographic data                                                                                                                          
  Age, y                                                                     70.5±9.3                  70.6±8.8                             0.975
  Male sex, n (%)                                                            22 (78.6)                 21 (60.0)                            0.116
  NYHA Class 1/2/3/4, n (%)                                                  ···                       21 (60.0)/14 (40.0)/0/0              
  Ischemic/nonischemic, n (%)                                                ···                       17 (48.6)/18 (51.4)                  
  HFrEF/HFpEF, n (%)                                                         ···                       24 (68.6)/11 (31.4)                  
  Comorbidity                                                                                                                               
  Hypertension, n (%)                                                        22 (78.6)                 21 (60.0)                            0.116
  Diabetes mellitus, n (%)                                                   9 (32.1)                  19 (54.3)                            0.079
  Dyslipidemia, n (%)                                                        23 (82.1)                 27 (77.1)                            0.626
  Atrial fibrillation, n (%)                                                 12 (42.9)                 11 (31.4)                            0.349
  Laboratory data                                                                                                                           
  Left ventricular ejection fraction, %                                      61.6±9.3                  37.4±13.1                            \<0.001
  B‐type natriuretic peptide, pg/mL[a](#jah34759-note-0002){ref-type="fn"}   50.8 (12.1--108.2)        346.6 (133.7--650.9)                 \<0.001
  Hemoglobin, g/dL                                                           12.9±1.6                  12.0±2.1                             0.045
  eGFR, mL/min per 1.73 cm^2^                                                56.2±13.3                 44.5±16.3                            0.003
  SpO~2~                                                                     96.9±1.5                  97.1±1.2                             0.412
  Medication                                                                                                                                
  RAS inhibitor, n (%)                                                       20 (71.4)                 24 (68.6)                            0.806
  Calcium channel blocker, n (%)                                             14 (50.0)                 15 (42.9)                            0.572
  β‐Blocker, n (%)                                                           18 (64.3)                 24 (68.6)                            0.720
  Inotropic agent, n (%)                                                     0                         11 (31.4)                            \<0.001
  Statin, n (%)                                                              17 (60.7)                 19 (54.3)                            0.608
  Antidiabetic agents, n (%)                                                 8 (28.6)                  15 (42.9)                            0.242
  Antiplatelet agent, n (%)                                                  13 (46.4)                 15 (42.9)                            0.777
  Anticoagulant, n (%)                                                       11 (39.3)                 18 (51.4)                            0.337
  Psychological testing                                                                                                                     
  VFT                                                                        11.1±4.6                  8.6±2.9                              0.010
  CES‐D                                                                      10.2±9.6                  11.6±8.0                             0.566
  STAI‐S                                                                     29.7±11.3                 42.1±9.6                             0.043
  STAI‐T                                                                     39.0±9.3                  40.5±10.7                            0.560
  MMSE                                                                       28.4±1.4                  26.4±3.0                             0.019

CES‐D indicates Center for Epidemiologic Studies Depression Scale; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MMSE, Mini‐Mental State Examination; NYHA, New York Heart Association; RAS, renin‐angiotensin‐ system; SpO~2~, percutaneous oxygen saturation; STAI‐S, State‐Trait Anxiety Inventory--State; STAI‐T, State‐Trait Anxiety Inventory--Trait; VFT, verbal fluency task.

Data are presented as median (interquartile range).

Changes in mean oxyhemoglobin concentrations in the HF and control groups are shown in Figure [1](#jah34759-fig-0001){ref-type="fig"}. The horizontal axis represents time, and the vertical axis represents changes in mean oxyhemoglobin concentrations (mM·mm) during VFT. Figure [2](#jah34759-fig-0002){ref-type="fig"} shows a topographic map of the differences in mean oxyhemoglobin concentrations. The mean oxyhemoglobin concentrations of right temporal lobe (channels 2, 13, 14, 32, 34, 35, 43, and 45), left temporal lobe (channels 8, 10, 18--21, 29--31, 39--42, and 50--52) and frontal region (channels 25--28, 36, 38, 46, 47, and 49) were significantly lower in the HF group than in the control subjects.

![Comparison of changes in mean oxyhemoglobin concentrations in the heart failure (red) and control subjects (blue).](JAH3-9-e014564-g001){#jah34759-fig-0001}

![Topographic map of the differences in mean oxyhemoglobin concentration changes between the HF and control subjects. The mean oxyhemoglobin concentrations of right temporal lobe (channels 2, 13, 14, 32, 34, 35, 43, and 45), left temporal lobe (channels 8, 10, 18--21, 29--31, 39--42, and 50--52) and frontal region (channels 25--28, 36, 38, 46, 47, and 49) were significantly lower in the HF group than in the control subjects. HF indicates heart failure.](JAH3-9-e014564-g002){#jah34759-fig-0002}

Next, we focused frontal and temporal brain activity (integral values of mean oxyhemoglobin concentrations in the frontal region and temporal lobes). Frontal and temporal brain activity was compared between the groups and are presented in Figure [3](#jah34759-fig-0003){ref-type="fig"}. Frontal and temporal brain activity were significantly lower in both the HF with reduced ejection fraction and HF with preserved ejection fraction than in the control subjects. In the multiple regression analysis to determine brain activity confounding factors (Table [2](#jah34759-tbl-0002){ref-type="table"}), HF was independently associated with frontal brain activity (β=−0.556, *P*\<0.001) and temporal brain activity (β=−0.499, *P*=0.003). In addition, as shown in Table [3](#jah34759-tbl-0003){ref-type="table"}, there were significant correlations between frontal brain activity and STAI‐S (*R*=−0.228, *P*=0.046), MMSE (*R*=0.414, *P*=0.017), and VFT (*R*=0.338, *P*=0.007), but not with CES‐D and STAI‐T. On the other hand, there was no significant correlation between temporal brain activity and CES‐D, STAI‐S, or MMSE, except for VFT (*R*=0.330, *P*=0.008).

![Comparisons of (**A**) frontal brain activity (integral values of mean oxyhemoglobin concentrations in the frontal region) and (**B**) temporal brain activity (integral values of mean oxyhemoglobin concentrations in the temporal lobes) between both HFrEF and HFpEF and control subjects. HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.](JAH3-9-e014564-g003){#jah34759-fig-0003}

###### 

Multiple Regression Analysis to Determine Brain Activity Confounding Factors

  Factors                              Univariate   Multivariate            
  ------------------------------------ ------------ -------------- -------- ---------
  Frontal brain activity                                                    
  Age                                  −0.109       0.413                   
  Male sex                             0.240        0.158                   
  Heart failure                        −0.599       \<0.001        −0.556   \<0.001
  Hypertension                         0.292        0.020          0.165    0.122
  Diabetes mellitus                    −0.118       0.357                   
  Dyslipidemia                         0.054        0.676                   
  Atrial fibrillation                  0.128        0.316                   
  Left ventricular ejection fraction   0.447        \<0.001        0.008    0.959
  B‐type natriuretic peptide           −0.231       0.071                   
  Hemoglobin                           0.142        0.267                   
  eGFR                                 0.151        0.237                   
  SpO~2~                               0.240        0.248                   
  RAS inhibitor                        0.086        0.500                   
  Calcium channel blocker              0.054        0.673                   
  β‐Blocker                            0.116        0.365                   
  Inotropic agent                      −0.153       0.231                   
  Statin                               −0.058       0.649                   
  Antidiabetic agents                  −0.153       0.231                   
  Antiplatelet agent                   −0.138       0.280                   
  Anticoagulant                        −0.102       0.427                   
  Temporal brain activity                                                   
  Age                                  −0.163       0.202                   
  Male sex                             0.206        0.106                   
  Heart failure                        −0.523       \<0.001        −0.499   0.003
  Hypertension                         0.258        0.041          0.149    0.192
  Diabetes mellitus                    −0.114       0.374                   
  Dyslipidemia                         0.125        0.331                   
  Atrial fibrillation                  0.231        0.068                   
  Left ventricular ejection fraction   0.381        0.002          −0.014   0.930
  B‐type natriuretic peptide           −0.042       0.745                   
  Hemoglobin                           0.051        0.691                   
  eGFR                                 0.151        0.239                   
  SpO~2~                               0.136        0.517                   
  RAS inhibitor                        0.081        0.530                   
  Calcium channel blocker              −0.103       0.422                   
  β=Blocker                            0.114        0.373                   
  Inotropic agent                      −0.127       0.321                   
  Statin                               0.095        0.460                   
  Antidiabetic agents                  −0.124       0.332                   
  Antiplatelet agent                   −0.102       0.428                   
  Anticoagulant                        −0.184       0.149                   

eGFR indicates estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; RAS, renin‐angiotensin system; SpO~2~, percutaneous oxygen saturation.

###### 

Correlation Analyses With Integral Values of Mean Oxyhemoglobin Concentrations in the Frontal Region and Temporal Lobes and Physiological Parameters

                                             Correlation (*R*)   *P* Value
  ------------------------------------------ ------------------- -----------
  Frontal brain activity (frontal region)                        
  VFT                                        0.338               0.007
  CES‐D                                      −0.160              0.233
  STAI‐S                                     −0.228              0.046
  STAI‐T                                     0.001               0.995
  MMSE                                       0.414               0.017
  Temporal brain activity (temporal lobes)                       
  VFT                                        0.330               0.008
  CES‐D                                      −0.252              0.059
  STAI‐S                                     −0.181              0.195
  STAI‐T                                     −0.071              0.611
  MMSE                                       0.077               0.578

CES‐D indicates Center for Epidemiologic Studies Depression Scale; MMSE, Mini‐Mental State Examination; STAI‐S, State‐Trait Anxiety Inventory--State; STAI‐T, State‐Trait Anxiety Inventory--Trait; VFT, verbal fluency task.

Discussion {#jah34759-sec-0015}
==========

In the present study, NIRS was used to evaluate the brain activity of HF patients. NIRS showed that frontal and temporal brain activity (an increase in cerebral oxyhemoglobin concentration in the frontal region and temporal lobes in response to the VFT), cognitive function (MMSE), and language ability (VFT) were lower, and anxiety status (STAI‐S) was higher in the patients with HF compared with the control subjects, despite no significant differences in SpO~2~ and depressive symptoms (CES‐D) between the 2 groups. In addition, frontal brain activity was associated with STAI‐S, MMSE, and VFT but not with CES‐D and STAI‐T. To the best of our knowledge, the current study appears to be the first to evaluate brain activity and psychological status in patients with HF using NIRS.

Regional CBF reduction in patients with HF appears in multiple brain sites, and those regions include vascular beds over the frontal, parietal, and occipital cortices, as well as the hippocampus, thalamus, and cerebellar areas; the majority of these brain sites also show brain tissue injury, as reported by previous studies using functional MRI.[18](#jah34759-bib-0018){ref-type="ref"}, [19](#jah34759-bib-0019){ref-type="ref"}, [20](#jah34759-bib-0020){ref-type="ref"} HF induces brain structural abnormalities that are associated with depressive symptoms and cognitive impairment.[18](#jah34759-bib-0018){ref-type="ref"}, [45](#jah34759-bib-0045){ref-type="ref"}, [46](#jah34759-bib-0046){ref-type="ref"} Multiple brain autonomic regulatory sites have been reported to show reduced CBF in patients with HF and include the hippocampus, thalamus, corona radiata, and cerebellar sites. The affected structures also show abnormal functional MRI signal responses to autonomic and cardiovascular challenges in HF.[47](#jah34759-bib-0047){ref-type="ref"} In the present study, with NIRS, mean oxyhemoglobin concentrations were lower in the HF group than in the control group in many of the 52 channels. The decrease in the mean oxyhemoglobin concentration in the frontal region was similar to the results seen in patients with depression.[48](#jah34759-bib-0048){ref-type="ref"}, [49](#jah34759-bib-0049){ref-type="ref"} Frontal hypoperfusion and frontal dysfunction have been observed in patients with depression,[50](#jah34759-bib-0050){ref-type="ref"}, [51](#jah34759-bib-0051){ref-type="ref"} which may be further associated with cognitive impairment.[52](#jah34759-bib-0052){ref-type="ref"}, [53](#jah34759-bib-0053){ref-type="ref"}

With respect to mood disorder, brain sites associated with mood regulation include the prefrontal cortex, cingulate, insula, hippocampus, amygdala, and cerebellar areas.[19](#jah34759-bib-0019){ref-type="ref"} These brain sites have been associated with injury in patients with depression only[54](#jah34759-bib-0054){ref-type="ref"}; however, the majority of these areas also showed reduced CBF in HF patients.[20](#jah34759-bib-0020){ref-type="ref"} The amygdala is also involved in anxiety regulation, and the bilateral amygdalae showed reduced CBF.[20](#jah34759-bib-0020){ref-type="ref"} In addition, amygdala--prefrontal cortex functional connectivity (ie, impaired frontal brain activity and relative overactivity of the amygdala) are reported to be associated with anxiety symptoms.[55](#jah34759-bib-0055){ref-type="ref"}, [56](#jah34759-bib-0056){ref-type="ref"} Reduced CBF in these regions likely contributes to tissue changes and thus has the potential to modify levels of depressive and anxiety symptoms in patients with HF. A decrease in the oxyhemoglobin concentration with NIRS reflects a decrease in frontal brain function in patients with depression or in a depressed state.[48](#jah34759-bib-0048){ref-type="ref"}, [49](#jah34759-bib-0049){ref-type="ref"} Although we could not fully explain the reason why frontal brain activity determined by NIRS was associated with anxiety status (STAI‐S) but not with depression (CES‐D), diagnostic sensitivity of CES‐D may have affected these results. Since patients with diagnosed depression were excluded, and mean CES‐D was low (ie, 10--11), CES‐D might not be necessarily appropriate for evaluating depressive symptom in the present study subjects.

With respect to cognitive impairment, patients with HF exhibit patterns of cortical alterations that overlap with cortical atrophy observed in Alzheimer disease, including lateral temporal and parietal regions.[45](#jah34759-bib-0045){ref-type="ref"}, [57](#jah34759-bib-0057){ref-type="ref"}, [58](#jah34759-bib-0058){ref-type="ref"}, [59](#jah34759-bib-0059){ref-type="ref"}, [60](#jah34759-bib-0060){ref-type="ref"}, [61](#jah34759-bib-0061){ref-type="ref"} Several brain sites including the hippocampus and prefrontal cortex regulate short‐term memory and decision making. Higher white matter hyperintensity volume is a risk factor associated with dementia in older community‐based residents.[62](#jah34759-bib-0062){ref-type="ref"} In subject without HF, increased left ventricular mass index corresponds to altered white matter microstructure, particularly among older adults with clinical symptoms of prodromal dementia.[63](#jah34759-bib-0063){ref-type="ref"} Cardiac function determined by compromised global longitudinal strain relates to worse episodic memory among older adults who are free of clinical dementia.[64](#jah34759-bib-0064){ref-type="ref"} In previous reports in patients with HF, CBF reductions appeared in the prefrontal cortex, a structure that plays critical roles in cognitive actions including executive decision making.[7](#jah34759-bib-0007){ref-type="ref"}, [8](#jah34759-bib-0008){ref-type="ref"}, [17](#jah34759-bib-0017){ref-type="ref"}, [57](#jah34759-bib-0057){ref-type="ref"} HF shows cerebral gray matter loss and is associated with cognitive impairment.[45](#jah34759-bib-0045){ref-type="ref"}, [58](#jah34759-bib-0058){ref-type="ref"} Hippocampal blood flow abnormality is associated with cognitive impairment in patients with HF.[60](#jah34759-bib-0060){ref-type="ref"}, [61](#jah34759-bib-0061){ref-type="ref"} A recent report showed that the degree of medial temporal lobe atrophy determined by MRI was strongly associated with the severity of cognitive impairment, whereas the extent of white matter hyperintensities was similar in patients and controls.[59](#jah34759-bib-0059){ref-type="ref"} Medial temporal lobe atrophy but not white matter lesion load seems to be related to cognitive impairment.[59](#jah34759-bib-0059){ref-type="ref"} Concordant with the present study, cerebral oxygenation is correlated with cognitive function assessed by the MMSE in patients with chronic kidney disease.[65](#jah34759-bib-0065){ref-type="ref"}

Study Limitations {#jah34759-sec-0016}
-----------------

The present study has several limitations. First, as a prospective cohort study of a single center with a relatively small number of patients, the present results may not be representative of the general population. Since VFT was used for NIRS testing, HF patients with New York Heart Association class III or IV were not enrolled. Although none of control subjects suffered from HF, most control subjects have hypertension, diabetes mellitus, dyslipidemia, or atrial fibrillation. Thus, patients with HF and control subjects in the present study might not be necessarily representative of a real‐world cohort. Second, because NIRS can evaluate only a shallow layer of the brain, deep layers (eg, hippocampus) or detail of regional areas could not be evaluated. Although functional MRI is used to accurately evaluate regional CBF in patients with HF, high costs and a large‐scale device or contraindication (eg, implantable device) in MRI interfere with simple and repeatable examination. NIRS is superior to MRI for easy‐to‐repeat measurements. Third, because of artifact, some NIRS signals in temporal areas could not be fully detected in some study subjects. NIRS signals during VFT may be influenced by skin blood flow. Fourth, although we excluded the presence of carotid artery stenosis or cerebral infarction, there may have been changes in cerebral oxyhemoglobin attributable to arteriosclerotic changes. Fifth, general condition may have affected the results of several physiological tests. Sixth, associations between brain activity determined by NIRS and each score of psychological testing (eg, depression, cognitive function, and anxiety) were roughly examined. These associations might be preliminary data. Therefore, the present results should be viewed as preliminary, and further studies with a larger population are needed.

Conclusions {#jah34759-sec-0017}
===========

Frontal brain activity assessed by NIRS was reduced and might be associated with high anxiety status and low cognitive function in patients with HF.
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